|
gptkbp:instanceOf
|
gptkb:drug
gptkb:anticoagulant
|
|
gptkbp:antidote
|
gptkb:andexanet_alfa
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2011 (US)
2011 (Europe)
|
|
gptkbp:ATCCode
|
gptkb:B01AF01
|
|
gptkbp:bioavailability
|
80-100% (10 mg dose)
|
|
gptkbp:brand
|
gptkb:Xarelto
|
|
gptkbp:CASNumber
|
366789-02-8
|
|
gptkbp:category
|
gptkb:anticoagulant
factor Xa inhibitor
|
|
gptkbp:contraindication
|
pregnancy
active pathological bleeding
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Bayer
|
|
gptkbp:discoveredBy
|
gptkb:Bayer_HealthCare
|
|
gptkbp:eliminationHalfLife
|
11-13 hours (elderly)
5-9 hours (young)
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
gptkb:C19H18ClN3O5S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rivaroxaban
|
|
gptkbp:interactsWith
|
CYP3A4 inhibitors
P-gp inhibitors
other anticoagulants
|
|
gptkbp:IUPACName
|
gptkb:5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
direct factor Xa inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
435.88 g/mol
|
|
gptkbp:monitors
|
renal function
signs of bleeding
|
|
gptkbp:notReversibleBy
|
gptkb:vitamin_A
|
|
gptkbp:patentExpired
|
2024 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
92-95%
|
|
gptkbp:riskFactor
|
increased bleeding risk with NSAIDs
increased bleeding risk with antiplatelet drugs
renal impairment increases exposure
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
dizziness
|
|
gptkbp:usedFor
|
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of venous thromboembolism after orthopedic surgery
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|